Memorial Health Services

1. AstraZeneca Pharmaceuticals LP $1,765,703 52 payments
2. AbbVie, Inc. $501,751 113 payments
3. CSL Behring $473,525 181 payments
4. Instylla Inc. $438,022 90 payments
5. AstraZeneca UK Limited $422,542 24 payments
6. Eli Lilly and Company $410,026 25 payments
7. Janssen Research & Development, LLC $346,010 58 payments
8. Mirati Therapeutics, Inc. $329,813 22 payments
9. Pfizer Inc. $311,823 69 payments
10. Genentech, Inc. $219,645 32 payments

1. Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. $488,537 1 payment
2. A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation $301,035 19 payments
3. A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) $265,535 2 payments
4. Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II $251,045 55 payments
5. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $222,479 126 payments
6. Strike-Pe $207,775 46 payments
7. A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke $204,717 55 payments
8. A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia $180,573 7 payments
9. Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed COVID19 Severe Disease $178,436 29 payments
10. A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY). $177,295 10 payments

1. Non-patient care $251,218 17 payments
2. Patient care $80,864 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.